International Society on Thrombosis and Haemostasis, Inc.

Abstract Guidelines 

Delegates who would like to present their work at the meeting, either orally or as a poster, are invited to submit an abstract for consideration by the Scientific Committee. 

There are no fees to submit an abstract; submit your abstract for free today!

Please find the full Abstract Submission Guidelines below:

Important Dates:

Abstract submission opens: December 1, 2015
Submission deadline: February 1, 2016, 11:59 p.m. Eastern Standard Time
Abstracts received after the deadline will not be accepted! 
Notifications to submitters: March 2016

Technical Requirements:

The internet abstract submission system works best with Internet Explorer 7.0 or higher or Mozilla Firefox 3.0 or higher. Cookies and JavaScript need to be enabled.


Abstracts can only be submitted online via the abstract submission form that can be found in the section "abstracts” on the official ISTH 2016 SSC website. Abstracts sent by post or email will not be accepted. No exceptions will be made.  The content of the abstract must be related to one of the topics listed below. To ensure smooth scoring of papers, the topic of your work must be selected during the submission process.

Main Topics:

  • Platelets (Basic & Clinical)
  • Coagulation Factors (Basic)
  • Thrombotic Disorders (Clinical)
  • Bleeding Disorders (Clinical)
  • Fibrinolysis and Proteolysis (Basic)
  • Vascular Biology
  • Hematopoiesis 

You will be asked to define which SSC Subcommittees and working groups your abstract most aligns with from the following list:

Section One - Platelets: 
Signal transduction in platelets
Molecular basis of inherited or acquired platelet disorders
Clinical aspects of Inherited platelet disorders
Clinical aspects of Acquired platelet disorders 
Anti-platelet therapy
Platelets in transfusion medicine
Experimental models
Section Two - Coagulation Factors
Coagulation pathways
Contact phase activation
Anticoagulant pathway
Exogenous hemostatic factors
Fibrinogen and other factors
Experimental models
Section Three - Thrombotic Disorders  
Deep vein thrombosis and pulmonary embolism
Arterial Thromboembolism
Genetic determinants and epidemiology
Anti-phospholipid syndrome
Disseminated intravascular coagulation
Thrombotic disorders in children
Thrombotic disorders in women
Cancer and thrombosis – clinical
Cancer and thrombosis – basic science
Antithrombotic therapy
Laboratory tests
Experimental models
Hemostatic assays
Section Four - Bleeding Disorders  
von Willebrand Disease

Laboratory tests
Experimental models
Other inherited bleeding disorders
Acquired bleeding disorders
Bleeding disorders in children
Bleeding disorders in women
Innovative therapies for bleeding disorders
Laboratory tests
Experimental models
Section Five - Fibrinolysis and Proteolysis
Plasminogen and plasminogen activators
Plasminogen activator inhibitors
PA system in organ-specific disorders
Fibrinogen and fibrin
New thrombolytic agents and drug design
Laboratory tests
Experimental models
Section Six - Vascular Biology

Endothelial cells
Inflammatory cells and cytokines
Vascular development
Endothelial Progenitor Cells
Experimental models
Microparticles/extracellular vesicles
Section Seven - Hematopoiesis
Megakaryocyte biology
Progenitor Cells and Stem Cells
Gene Therapy

Overall Guidelines

  • The abstract must address scientific questions, detail clinical observations, or contain primary scientific data.
  • Abstracts submitted for ISTH 2016 SSC are embargoed from the time of submission.  This means that the data in the abstract cannot be submitted to other meetings once submitted for the ISTH 2016 SSC meeting. Likewise, abstracts must contain original information, not submitted, published or presented elsewhere prior to submission.
  • The first / presenting author is responsible for ensuring that all authors have read the abstract and agreed to be co-authors.
  • Abstracts that have been submitted to a previous conference in the same specialty, published or unpublished, will not be accepted.
  • The Scientific Committee retains the right to reject abstracts containing previously submitted or presented data as they see fit.
  • All research and studies in submitted abstracts that involve human subjects or experimental animals must comply with the Declaration of Helsinki.
  • In clinical studies, please state whether informed consent was obtained and whether the study was approved by a recognized medical ethics committee.
  • If off-label use of drugs was involved in the study, please state this clearly.
  • If the research included in your abstract was supported by a pharmaceutical or diagnostics company, you can indicate this when submitting your abstract.
  • Please indicate the funding agency of your work if applicable.
  • The abstract title and text may not contain trade names. The Scientific Committee reserves the right to replace trade names in accepted abstracts.
  • Do not slice results from the same study into multiple abstracts. The Scientific Committee reserves the right to reject abstracts when inappropriate slicing of data is suspected.
  • Similarly, do not submit a copy or close copy of an abstract under more than 1 topic. Abstracts that appear to be submitted multiple times under different topics will be rejected.
  • Abstracts should be submitted in clear English to allow the reviewers to focus on the scientific content of the abstract. Non-English speaking authors are encouraged to have their abstract checked for grammar and spelling.
  • For standardization, the acceptable length of the abstract is a maximum of 2,000 characters including non-visible characters, such as spaces and line breaks. This does not include the author’s details, titles, keywords, tables and graphs.
  • Abstracts can be saved in "Draft” status to be re-edited and modified until the submission deadline (February 1, 2016, 11:59 EST). Therefore, the submitter will be required to create a user account.
  • The submitted / draft abstracts cannot be edited after the submission deadline.
  • Abstracts fulfilling all criteria can be saved and submitted. You can still make edits to abstracts that have been submitted, but you will need to re-submit it before the deadline to be considered.
  • Only abstracts that have been submitted properly will be considered for the meeting.
  • The abstract should be structured into the following sections:
    • A title which clearly indicates the nature of the investigation
    • Background
    • Aims
    • Methods, which should contain sufficient information to be able to understand the experimental design, the analytical techniques and the statistics used in the study
    • Results, which should contain objective data to answer the scientific question(s). A maximum of two total tables or graphs may be inserted into this section. 
    • Conclusion (or Conclusions) which should provide only conclusions of the study directly supported by the results, along with implications for clinical practice, avoiding speculation and overgeneralization.
    • Keywords: please choose four keywords, these will NOT count towards the 2,000 character count limit. 
    • Images and graphs may be inserted with a maximum size of 600 x 800 pixels
    • Tables are allowed with a maximum size of 10 columns x 10 rows. Characters in your table will NOT count towards your 2,000 character count.
    • Adding Co-authors: please fill out the family names, first names, and institute, city, country and email addresses of the co-authors.

  • Conflict of interest: It is the intent of the ISTH to provide high-quality sessions focused on educational content that is free from commercial influence or bias. Thus the submitting author of an abstract is requested to declare any potential conflicts of interest for all authors during abstract submission.
  • Abbreviations should be defined.
  • The submission of an abstract constitutes a formal commitment by the submitting (presenting) author to present the abstract (if accepted) in the session and the time assigned by the Scientific Committee. Registration fees will not be waived.
  • The presenting author of the abstract must be registered for the meeting. 
  • Please ensure your abstract does not contain spelling, grammar, or scientific mistakes, as it will be reproduced exactly as submitted. Linguistic accuracy is your responsibility. No proof reading will be done.
  • The registration fees for the presenting author will not be waived.
  • No revisions can be made after the abstract deadline.

Language Setting of Your Keyboard

The keyboard configuration of computers in non-Western countries may cause problems with the printing of the abstracts when special non-Western characters are used. To avoid these problems the language setting of your computer should be changed. To do this select "Start" then Settings", then "Control Panel" and then choosing "Keyboard." Once in this menu, set the language of your computer to English (United States) or US (International). Next, open MS Word (or the word processing software you are using) and set the font type to Arial.  In the preparation of your abstract, if you require certain special characters that are not available, (e.g. '±', '®', 'μ'), use the insert symbol feature (special characters). To do this, select Arial as the font (unicoded, if possible), then select the required character, and copy and paste the symbol into the text of the abstract. If a special character is still not available, describe the character, e.g. 'alpha’.

Browser Font Preference

Before submitting your abstract, select Unicode as the preferred font. If Unicode is not available, please select Western.

After Submission

An international panel of experts will review the abstracts. Each abstract will be reviewed by 4-6 different experts.

The reviewers will judge the abstracts according to the following criteria:

  1. Is the abstract original?
  2. Does it address an important scientific question?
  3. Is the abstract clearly written with all salient facts?
  4. Does the work adhere to ethical guidelines?
  5. Is there evidence of statistical method if appropriate?
  6. Are the conclusions justified by the results?

The first author will be notified in March 2016, at the email address provided during submission, about whether or not their abstract has been accepted.

Poster presenters will be informed about the date of the poster exhibition and will receive guidelines for their preparation and presentation. Posters will be organized within the session using the topics chosen by the submitter in the online system.

All accepted abstracts will be published as addendum supplement to the Journal of Thrombosis and Haemostasis and will be made available on the ISTH 2016 SSC website at the time of the meeting. 

Withdrawal Policy

If authors wish to withdraw their abstracts from presentation or publication they are requested to send a letter via e-mail to before April 1, 2016.

Withdrawn abstracts cannot be presented nor will these be published.

Procedure Abstract Review & Selection

All abstracts submitted by February 1 will be reviewed by an international panel of experts (representing all subspecialties from a large number of countries). Within 10 days after the closure of the abstract submission, the reviewers are requested to read and score each abstract in their category based on scientific merit. The scoring system is a scale ranging from 1 to 10, with a qualitative explanation of each grade. Once all abstracts have been reviewed, the scores are normalized and averaged.

Travel Grants

The Scientific Committee will reward abstracts of outstanding quality and provide the submitting author with a Travel Grant to attend the SSC 2016 meeting. Two categories of Travel Grants will be available in limited number to the abstract submitters.

Young Investigator Award

The Young Investigators Awards are provided in the form of travel grants to medical trainees and young scientists (under 35 years of age as of May 24, 2016) who submit a highly rated abstract. Travel grants are specifically intended to help with travel to the Meeting. In order to be considered for an award, the Young Investigator must be the first author on an abstract submitted to the Meeting. 

The highest rated abstract in each SSC Subcommittee Category will be selected for an Oral Presentation in that session and will be eligible for an ISTH Travel Grant. Please note that you need to be willing to submit this presentation orally.

To be eligible for the award, the recipient must attend the Meeting, and members of the ISTH will be given priority.

Reach-the-World Award

The ISTH will award travel grants to clinicians and scientists from developing countries (countries classified by the World Bank as low income, lower-middle income, or upper-middle income)
 to help subsidize travel to the Meeting (a copy of current passport showing country of residence will be required). Those that are the presenter and first author of an abstract submitted to the Meeting will be prioritized. To be eligible for the award, the recipient must attend the Meeting.

Please select the relevant award on the drop down on the abstract submission form to indicate you wish to apply for this grant. 

For those not submitting abstracts, please apply to and explain how this grant and meeting will be of benefit in driving up standards of care for patients. To be eligible for the award, the recipient must attend the Meeting. 


Problems Submitting?

If you experience any kind of problem or if you have questions, please do not hesitate to contact PharmaService at